StreetInsider.com News Articles

Form 4 IRIDEX CORP For: Oct 02 Filed by: Novel Inspiration International Co., Ltd.

Tue, 13 Oct 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20261013/27177838.html

Iridex study shows IOP reduction with MicroPulse glaucoma therapy

Mon, 12 Oct 2026 07:02:06 -0400

Iridex Corporation (NASDAQ: IRIX) announced the publication of a two-year retrospective clinical study in the International Journal of Ophthalmology showing reduced intraocular pressure (IOP) and lower medication use in glaucoma patients treated with transscleral laser therapy (TLT) using its MicroPulse technology.

The study, led by Michele Lanza, MD, of the Università della Campania Luigi Vanvitelli in Naples, Italy, evaluated 84 eyes of 53 patients with primary open-angle glaucoma or primary angle-closure glaucoma. The Iridex Cyclo G6 Laser with the MicroPulse P3 Delivery Device was used in all cases.

At 24 months, mean IOP declined from 22.32 mmHg at baseline to 14.05 mmHg.

Study backs Iridex MicroPulse therapy for glaucoma over two years

Mon, 12 Oct 2026 07:01:29 -0400

Iridex Corporation (NASDAQ: IRIX) announced the publication of a two-year retrospective clinical study in the International Journal of Ophthalmology showing favorable outcomes with transscleral laser therapy using the company's MicroPulse technology in patients with primary glaucoma.

The study, led by Michele Lanza, MD, of the Università della Campania Luigi Vanvitelli in Naples, Italy, evaluated 84 eyes of 53 patients diagnosed with either primary open-angle glaucoma or primary angle-closure glaucoma. The Iridex Cyclo G6 Laser with the MicroPulse P3 Delivery Device was used in all treatments.

At 24 months, mean intraocular pressure fell from 22.32 mmHg at baseline to 14.05 mmHg. The mean

Iridex Announces the Publication of Two-Year Independent Study Supporting Benefits of MicroPulse® Technology for Early to Advanced Glaucoma

Mon, 12 Oct 2026 07:00:00 -0400

SAN JOSE, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader in innovative laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced the publication of a two-year clinical study demonstrating favorable outcomes with transscleral laser therapy (TLT) using MicroPulse® Technology (referred to as MicroPulse TLT) in patients with early, moderate, and advanced primary glaucoma.

“These two-year results are particularly meaningful because they show sustained IOP reduction and reduced medication burden in patients with early-stage glaucoma, as well as in those with moderate and advanced

Iridex Announces the Publication of Two-Year Independent Study Supporting Benefits of MicroPulse® Technology for Early to Advanced Glaucoma

Mon, 12 Oct 2026 07:00:00 -0400

Iridex Announces the Publication of Two-Year Independent Study Supporting Benefits of MicroPulse® Technology for Early to Advanced Glaucoma

Mon, 12 Oct 2026 07:00:00 -0400

Study reports sustained IOP reduction and reduced medication burden over 24 months

SAN JOSE, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader in innovative laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced the publication of a two-year clinical study demonstrating favorable outcomes with transscleral laser therapy (TLT) using MicroPulse^® Technology (referred to as MicroPulse TLT) in patients with early, moderate, and advanced primary glaucoma.

“These two-year results are particularly meaningful because they show sustained IOP reduction and reduced medication burden in patients with

Iridex Announces the Publication of Two-Year Independent Study Supporting Benefits of MicroPulse® Technology for Early to Advanced Glaucoma

Mon, 12 Oct 2026 07:00:00 -0400

Study reports sustained IOP reduction and reduced medication burden over 24 months

SAN JOSE, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader in innovative laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced the publication of a two-year clinical study demonstrating favorable outcomes with transscleral laser therapy (TLT) using MicroPulse^® Technology (referred to as MicroPulse TLT) in patients with early, moderate, and advanced primary glaucoma.

“These two-year results are particularly meaningful because they show sustained IOP reduction and reduced medication burden in patients with

Form 4 IRIDEX CORP For: Mar 25 Filed by: Lin Shih-Yao David

Wed, 07 Oct 2026 06:10:00 -0400

si-local-file:///var/storage/secattach/20261007/27157568.html

Form 4 IRIDEX CORP For: Mar 25 Filed by: Lin Shih-Yao David

Wed, 07 Oct 2026 06:08:00 -0400

si-local-file:///var/storage/secattach/20261007/27157549.html

Form 4 IRIDEX CORP For: Mar 25 Filed by: Lin Shih-Yao David

Wed, 07 Oct 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20261007/27157530.html

Form 4 IRIDEX CORP For: Oct 01 Filed by: Mercer Patrick

Mon, 05 Oct 2026 14:19:00 -0400

si-local-file:///var/storage/secattach/20261005/27148225.html

Iridex Completes Relocation of Manufacturing Facility to San Jose, California

Mon, 05 Oct 2026 07:00:00 -0400

Company Expects to Realize Approximately $600,000 in Annualized Cost Savings

SAN JOSE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced that it has completed the relocation of its manufacturing facility from Mountain View, California to a new facility in San Jose, California.

“We are pleased to announce the successful relocation of our manufacturing facility. This was a key component of our plan to reduce expenses and improve profitability,” said Patrick Mercer,

Iridex Completes Relocation of Manufacturing Facility to San Jose, California

Mon, 05 Oct 2026 07:00:00 -0400

Company Expects to Realize Approximately $600,000 in Annualized Cost Savings

“We are pleased to announce the successful relocation of our manufacturing facility. This was a key component of our plan to reduce expenses and improve profitability,” said Patrick Mercer,

Form 4 IRIDEX CORP For: Sep 16 Filed by: Dizon Romeo R

Wed, 16 Sep 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260916/27070594.html

Form 4 IRIDEX CORP For: Sep 14 Filed by: Dizon Romeo R

Mon, 14 Sep 2026 11:39:00 -0400

si-local-file:///var/storage/secattach/20260914/27057144.html

Form 4 IRIDEX CORP For: Sep 10 Filed by: Dizon Romeo R

Thu, 10 Sep 2026 11:54:00 -0400

si-local-file:///var/storage/secattach/20260910/27047180.html

Form 4 IRIDEX CORP For: Aug 24 Filed by: Dizon Romeo R

Mon, 24 Aug 2026 12:03:00 -0400

si-local-file:///var/storage/secattach/20260824/26966439.html

Form 4 IRIDEX CORP For: Aug 24 Filed by: Dizon Romeo R

Mon, 24 Aug 2026 12:03:00 -0400

si-local-file:///var/storage/secattach/20260824/26966439.html

Form 10-Q IRIDEX CORP For: Jul 04

Tue, 18 Aug 2026 16:54:00 -0400

si-local-file:///var/storage/secattach/20260818/26945156.html

Form 10-Q IRIDEX CORP For: Jul 04

Tue, 18 Aug 2026 16:54:00 -0400

si-local-file:///var/storage/secattach/20260818/26945156.html

Form 8-K IRIDEX CORP For: Aug 18

Tue, 18 Aug 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20260818/26945124.html

Form 8-K IRIDEX CORP For: Aug 18

Tue, 18 Aug 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20260818/26945124.html

Iridex Corp (IRIX) Misses Q2 EPS by 5c

Tue, 18 Aug 2026 16:26:16 -0400

Iridex Corp (NASDAQ: IRIX) reported Q2 EPS of ($0.07), $0.05 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $12.6 million versus the consensus estimate of $14.13 million.

For earnings history and earnings-related data on Iridex Corp (IRIX) click here.

Iridex Reports Second Quarter 2026 Financial Results

Tue, 18 Aug 2026 16:05:00 -0400

MOUNTAIN VIEW, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today reported financial results for the second quarter ended July 4, 2026.

Second Quarter 2026 Financial Highlights

Generated total revenue of $12.6 million, compared to $13.6 million in the prior year period
Cyclo G6^® product family revenue was $3.9 million, representing growth of 19% year-over-year compared to $3.3 million in the prior year period
- Sold 17,700 Cyclo G6 probes compared to 13,100

Iridex Reports Second Quarter 2026 Financial Results

Tue, 18 Aug 2026 16:05:00 -0400

Second Quarter 2026 Financial Highlights

Generated total revenue of $12.6 million, compared to $13.6 million in the prior year period
Cyclo G6^® product family revenue was $3.9 million, representing growth of 19% year-over-year compared to $3.3 million in the prior year period
- Sold 17,700 Cyclo G6 probes compared to 13,100